Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian Patients

Summary

Retrospective prospective cohort study aimed at Assessing the predictors to the response to the antiviral combined therapy with pegylated Interferon (Both types: Alfa 2 A and Alfa 2 B) in hepatitis C virus infected Egyptian patients.

Conditions

• Hepatitis C, Chronic

Sponsors & Collaborators

• Cairo University

  lead OTHER

Principal Investigators

• Gamal Esmat, MD · Cairo University

• Abdelrahman Zerki, PHD · Cairo University

• Wahid Doss, MD · Cairo University

• Maissa El Raziky, MD · Cairo University

• Gamal Sheha, MD · Cairo University

• Tarneem Darwish, MSc. · Cairo University

• samy zaki, MD · Cairo University

• Magdi El-Serafy, MD · Cairo Universty

• Fathalla Sedky, MD · Cairo University

• Ahmed M Nasr, MD · Cairo University

• Mostafa Gabr, MD · Cairo University

• Ali kassem, MD · Cairo University

• Ibrahim Metawea, MD · Cairo University

• Noaman Al-Garem, MD · Cairo University

• Hassan Hamdy, MD · Cairo University

• Tawheed Mwafy, MD · Cairo University

• Khalil A Khalil, MD · Cairo University

• Magdy Atta, MD · Cairo University

• Osama E Salem, MD · Cairo University

• Mohamed A Afify, MD · Cairo University

• Mohamed S Al-Shazly, MD · Cairo University

• Hamdy Mahfouz, MD · Cairo University

• Mustafa Gabr, MD · Cairo University

• Monquez Motaea, MD · Cairo University

• Hossam Abdel-Latif, MD · Cairo University

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2011-01-31

Primary Completion

2016-01-31

Completion

2017-01-31

Countries

• Egypt

Study Locations